Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
Tags: Iroko Pharmaceuticals, FDA, ZORVOLEX, osteoarthritis pain
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
US-based Iroko Pharmaceuticals has entered into a $75m debt facility agreement with an affiliate of OrbiMed Advisors (OrbiMed) to support general business operations and the launch of Zorvolex (diclofenac). Zorvolex is the first and only ...
US-based iCeutica announced that its partner Iroko Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to market ZORVOLEX (diclofenac) capsules, a non-steroidal anti-inflammatory drug (NSAID) that utilizes ...